GlobeNewswire by notified

Important Milestone Reached for Evaxion Biotech’s EVX-01 Personalized Cancer Therapy

Share

COPENHAGEN, Denmark, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, reached an important milestone announcing today that it had enrolled its first patient in the global phase 2b clinical trial of EVX-01, the Company’s personalized cancer therapy for the treatment of melanoma.

In the company’s first phase 2b clinical trial, Evaxion is evaluating the efficacy and safety of EVX-01 in adults with metastatic melanoma. The trial is being conducted globally at clinical sites across the US, Europe, and Australia in collaboration with Merck & Co., Inc., which is supplying the trial with its PD-1 inhibitor, KEYTRUDA®.

Patients enrolled in the phase 2b clinical trial will receive standard of care treatment along with KEYTRUDA® in combination with EVX-01. Evaxion is responsible for the conduct of the trial and Merck will supply the required KEYTRUDA®. Evaxion and Merck will continue to collaborate as the data mature.

Erik Heegaard, Evaxion’s Chief Medical Officer, said:

“We are extremely proud to take EVX-01 into the next clinical development phase, enrolling our first patient in the clinic. We believe that this will help to support our efforts in developing new and more efficacious treatments for patients suffering from malignant melanoma. With this phase 2b trial, we are addressing a major unmet medical need in an indication that has become a multi-billion-dollar market. Together with our collaborators at Merck, we hope to further validate the promising data generated in our phase 1/2a study, which we believe may potentially pave the way for much needed improvement in the treatment landscape for melanoma and possibly other cancers.”

Background:

  • EVX-01 is a novel personalized cancer immunotherapy based on Evaxion’s proprietary PIONEER™ AI technology, for the treatment of patients with melanoma.
  • Data from the Phase 1/2a clinical trial of EVX-01 has shown that 67% of nine patients benefitted from EVX-01 in combination with a PD-1 inhibitor (KEYTRUDA®) for the treatment of metastatic melanoma, compared to the historical data of only 40% benefiting from a PD-1 inhibitor alone
  • 22% of the patients in the Phase 1/2a clinical trial achieved a complete response (full recovery) with EVX-01 in combination with a PD-1 inhibitor (KEYTRUDA®).
  • The first patient in the Phase 2b clinical trial has now been enrolled
  • The Company anticipates interim topline data readout in H2 of 2023
  • For further information, please refer to clinicaltrials.gov: KEYNOTE – D36 NCT05309421

KEYTRUDA® is a registered trademark of Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA.

About Evaxion
Evaxion Biotech A/S is a clinical-stage biotech company developing AI-powered immunotherapies. With our proprietary and scalable AI technology, we decode the human immune system to discover and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has a broad pipeline of novel product candidates, including three personalized cancer immunotherapies. It is located in Hørsholm, Denmark, and currently has 70 employees.

For more information
Evaxion Biotech A/SLifeSci Advisors LLC
Erik HeegaardCorey Davis, Ph.D.
Chief Medical OfficerManaging Director
ehe@evaxion-biotech.comcdavis@lifesciadvisors.com
+45 20810282+1 (212) 915 2577

Forward-looking statement
This announcement contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this announcement regarding the Company’s future operations, plans and objectives are forward-looking statements. Although the Company believes its expectations are based on reasonable assumptions, all statements other than statements of historical fact included in this announcement about future events are subject to (i) change without notice and (ii) factors beyond the Company’s control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as “target,” “believe,” “expect,” “hope,” “aim,” “intend,” “may,” “might,” “anticipate,” “contemplate,” “continue,” “estimate,” “plan,” “potential,” “predict,” “project,” “will,” “can have,” “likely,” “should,” “would,” “could,” and other words and terms of similar meaning or the negative thereof. Actual results may differ materially from those indicated by such forward-looking statements as a result of various factors, including but not limited to: risks associated with the Company’s financial condition and need for additional capital; risks related to the Company’s development work; cost and success of the Company’s product development activities and preclinical and clinical trials; risks related to commercializing any approved pharmaceutical product developed using the Company’s AI platform technology, including the rate and degree of market acceptance of the Company’s product candidates; risks related to the Company’s dependence on third parties including for conduct of clinical testing and product supply and manufacture; risks associated with the Company’s inability to enter into partnerships; risks related to government regulation; risks associated with protection of the Company’s intellectual property rights; risks related to employee matters and managing growth; risks related to the Company’s ADSs and ordinary shares, risks associated with the pandemic caused by the coronavirus known as COVID-19 and the emergence and prevalence of COVID-19 variants, such as Delta and Omicron, and specific related variants such as the Omicron BA.4 and BA.5 variants, risks associated with the hostilities between Ukraine and Russia and other risks and uncertainties affecting the Company’s business operations and financial condition.

Forward-looking statements are subject to inherent risks and uncertainties beyond the Company’s control that could cause the Company’s actual results, performance, or achievements to be materially different from the expected results, performance, or achievements expressed or implied by such forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to the Company’s business in general, see the risks described in the “Risk Factors” section included in the Company’s Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission (SEC) on March 31, 2022 and the Company’s current and future reports filed with, or furnished to the SEC. Any forward-looking statements contained in this announcement speak only as of the date hereof, and except as required by law, the Company assumes no obligation to update these forward-looking statements publicly, or to update the reasons actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Lytho Appoints Geert Bruinink to Lead Operations in Europe27.9.2022 10:00:00 CEST | Press release

Seasoned Executive Brings a Mix of General Management and Sales Leadership as the Company Expands Reach in Europe for its Creative Workflow and Digital Asset Management (DAM) Software AMSTERDAM, the Netherlands and RALEIGH, N.C., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Lytho, a creative operations platform providing creative workflow and digital asset management (DAM) tools to brand and creative teams, today announced it has hired Geert Bruinink as its Country Manager based in The Netherlands. He will report to Lytho CEO Douglas Thede and have overall responsibility for the company’s European sales and operations. “Geert brings a proven track record of general management and sales leadership skills to Lytho as we extend our presence in Europe,” said Thede. “We’ve seen strong demand for our software because in-house creative teams have grown, and our tools reduce the natural complexity that comes with that growth. We’re thrilled to welcome Geert as a Lythonian and look forward to his contrib

Conagen unveils commercial production of high-purity non-GMO salidroside27.9.2022 10:00:00 CEST | Press release

Ideal for adaptogen supplement solutions and natural preservatives in food and beverages. Bedford, Mass., Sept. 27, 2022 (GLOBE NEWSWIRE) -- Conagen announced the commercialization of its 99% high-purity salidroside made by bioconversion technology, an active ingredient from the herbal plant Rhodiola rosea (golden root). Its strong antioxidant properties as an adaptogen are associated with reducing inflammation, protecting against oxidative stress in cells, and providing relief from depression, fatigue, and stress. Salidroside has also been used to alleviate high altitude sickness. Unlike other salidroside products currently on the market, Conagen’s salidroside is non-GMO. Conagen leveraged its industry-leading bioconversion technology to produce clean, sustainable salidroside, identical to the compound naturally found in the Rhodiola rosea plant --- the same technology used to produce non-GMO Rebaudioside M, other steviol glycosides, and bitter blockers for sugar reduction solutions w

SATO announces new Sustainability Programme spearheaded by sustainable housing and wellbeing in communities27.9.2022 10:00:00 CEST | Press release

SATO Corporation Press release 27 September 2022 at 11:00 am SATO, one of Finland’s largest rental housing providers, has released its new Sustainability Programme for 2023–2026.The programme is themed on sustainable housing, wellbeing in communities and sustainable profitability. SATO is one of Finland’s biggest rental housing providers, holding around 25,000 rental homes occupied by some 50,000 residents. SATO’s new Sustainability Programme, the second of its kind, builds on three pillars: environmental, social as well as economic sustainability and sustainable governance. “Last year, we made sustainability one of the three cornerstones of our strategy. Sustainability is a key component in our long-term value generation for our various stakeholders. It is about concrete actions that can be seen in everything we do. We aim to be a forerunner in sustainable rental housing,” says Susanna Kari Gonzaléz, Sustainability Manager at SATO. SATO’s sustainable operating principles lay the found

Duck Creek Technologies Focuses on Enhancing Distribution Channels and Speed to Market for Insurers with UK / EMEA Expansion of Duck Creek Producer27.9.2022 09:30:00 CEST | Press release

London, Sept. 27, 2022 (GLOBE NEWSWIRE) -- Duck Creek Technologies (NASDAQ: DCT), the intelligent solutions provider defining the future of property and casualty (P&C) insurance, is pleased to announce today the international expansion of Duck Creek Producer, a cutting-edge platform for enhancing the relationships between insurers and brokers and accelerating speed-to-market for distributing new products. Duck Creek Producer was launched in the US in 2020 and has been gaining strong traction, including a recent implementation for Arbella Insurance Group, a North American underwriter of personal and commercial lines insurance products. Duck Creek Producer’s functionality has now been extended globally, with the UK / EMEA markets a key growth area. Duck Creek Producer enables insurers to maximise operational efficiency by delivering genuinely valuable and satisfying portal experiences that result in more productive and loyal agents, brokers and other intermediaries. Incorporating extensi

Hexagon Ragasco, the world’s leading manufacturer of composite LPG cylinders, awarded new Environmental Product Declaration27.9.2022 09:00:00 CEST | Press release

Hexagon Ragasco, a Hexagon company and world leading manufacturer of LPG composite cylinders – was awarded a new Environmental Product Declaration (EPD) from EPD-Norway covering the entire lifetime of their cylinders from cradle to grave. Hexagon Ragasco’s cylinders are produced at the company’s fully automated manufacturing plant in Raufoss, Norway. During the past 22 years, Hexagon Ragasco has sold over 20 million cylinders to close to 100 countries. Value of an Environmental Product Declaration (EPD) An EPD discloses a product’s life cycle environmental impact and helps users to identify sustainable products. Both the underlying Life-Cycle Assessment (LCA) and the EPD are based upon international standards. Furthermore, it contains quantified information that enables comparison between products from the same product category and declares its environmental footprint towards predetermined environmental factors; one being the product’s carbon footprint. Hexagon Ragasco’s first EPD cove